8) Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 2017; 22: 1502-8.9) Sato T, Kawabata T, Kumondai M, Hayashi N, Komatsu H, Kikuchi Y, et al. Effect of organic anion transporting polypeptide 1B1 on plasma concentration dynamics of clozapine in patients with treatment-resistant schizophrenia. Int J Mol Sci 2024; 25: 13228. 10) Sato T, Suzuka M, Sato Y, Iwabuchi R, Kobayashi D, Ogura J, et al. Development of a simultaneous analytical method for clozapine and its metabolites in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry with linear range adjusted by in-source collision-induced dissociation. Biomed Chromatogr 2021; 35: e5094.11) Ciută AD, Nosol K, Kowal J, Mukherjee S, Ramírez AS, Stieger B, et al. Structure of human drug transporters OATP1B1 and OATP1B3. Nat Commun 2023; 14: 5774.12) Shan Z, Yang X, Liu H, Yuan Y, Xiao Y, Nan J, et al. Cryo-EM structures of human organic anion transporting polypeptide OATP1B1. Cell Res 2023; 33: 940-51.13) Jiménez-Fernández S, Gurpegui M, Correll CU, de Leon J, Schoretsanitis G. A systematic review of clozapine concentration-dose ratio from therapeutic drug monitoring studies in children and adolescents treated with clozapine for mental disorders. Ther Drug Monit 2024; 46: 170-80.14) Yada Y, Kitagawa K, Sakamoto S, Ozawa A, Nakada A, Kashiwagi H, et al. The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study. Acta Psychiatr Scand 2021; 143: 227-37.15) Lin SK. Racial/ethnic differences in the pharmacokinetics of antipsychotics: focusing on east Asians. J Pers Med 2022; 12: 1362.文 献701）Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27: 539-43.2) Kikuchi Y, Kurosawa M, Sakata M, Takahashi Y, Yamamoto K, Tomita H, et al. Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals. Br J Psychiatry 2024; 225; 492-8.3) de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry 2022; 55: 73-86.4) John AP, Kecanovic A. Unusually high serum levels of clozapine associated with genetic polymorphism of CYP3A enzymes. Asian J Psychiatr 2021; 57: 102126.5) Watanabe K, Misaka S, Kanno‐Nozaki K, Chiyoda T, Suzuki Y, Sato A, et al. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4. Br J Clin Pharmacol 2024; 90: 354-9.6) Kikuchi Y, Sato T, Murakami K, Otsuka T, Machida T, Yoshikawa K, et al. Concomitant use of clozapine and suvorexant associated with doubling of clozapine plasma levels: a case report. J Clin Psychopharmacol 2024; 44: 185-7.7) Akamine Y, Sugawara-Kikuchi Y, Uno T, Shimizu T, Miura M. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann Clin Biochem 2017; 54: 677-85.
元のページ ../index.html#84